

Hello,

My name is Jason Cranford. I have been a licensed cultivator and dispensary owner in Colorado for the past 5 years. I am the founder and Director of a nonprofit that assists families with cannabinoid education, doctor visits and safe access to laboratory tested Cannabis derived medicines. Dr. Allen Shakleford is a Board Member of the nonprofit and provides medical advice to the families and patients receiving our assistance.

I have spent the last two years working with a phyto pharmaceutical company and researching cannabinoids on a clinical level. I am currently involved with a Colorado University in a single blind research study on CBD and seizure control involving 100 pediatric patients. Through this study, I am working with a Colorado pediatric neurologist with over 25 years of experience treating and monitoring patients. The results of the study will be published through Pub Med and the National Institute of Health.

The research model developed for this trial is a protocol designed to protect the University from the risk of losing federal funding. This model can be duplicated in other states. This type of clinical research is necessary to determine the efficacy of milligrams of CBD or THC per pound of body weight in patients.

We know through anecdotal evidence and patient testimonials that cannabis alleviates the symptoms of numerous medical conditions, but we do not know why or at what dosage. Once these questions have been answered through controlled research studies, a standardized dose of cannabinoids that is effective for individual medical conditions can be created.

There are hundreds of compounds found in Cannabis, yet only a fraction of these cannabinoids have been identified. Research studies from all over the globe are showing that the majority of these cannabinoids are medically significant and provide therapeutic benefits associated with numerous medical conditions.

For example, specific CBD:THC ratios are currently being used in Colorado to treat estrogen positive cancers like breast and ovarian cancer. CBD has been shown to slow metastases of breast cancer while THC can cause apoptosis, or the death of cancer cells. This research is supported by the National Cancer Institute and the National Institute of Health. (Insert reference? Maybe McAllister??)

While current case studies and research can provide guidance, it is important to understand that this is not a "one size fits all" type of medicine. Understanding the dosing and cannabinoid ratios associated with various ailments is our obligation to patients.

Allowing clinical research of all cannabinoids will ensure that anyone who can benefit from the use of this plant will have it as an option. No patient should be left behind because they are not suffering from a politically correct medical condition.

Thank You.